血清肿瘤标志物检测在盆腔良恶性妇科肿瘤诊断与鉴别诊断中的意义

Significance of serum tumor markers in the diagnosis and differential diagnosis of pelvic benign and malignant gynecological tumors

目的探讨盆腔良恶性妇科肿瘤采取血清肿瘤标志物检测的诊断及鉴别意义。方法选择2016年7月5日~12月23日在我院收治的盆腔妇科肿瘤患者50例作为研究对象,根据肿瘤性质分为良性组及恶性组(各25例),另取同期50例健康体检者为对照组。所有患者均予以血清肿瘤标志物检测,观察检测阳性情况及生化指标含量。结果恶性肿瘤组CA153、CA125阳性率分别为52.00%、92.00%,高于良性肿瘤组(4.00%、60.00%),差异有统计学意义(P<0.05),两组CEA、AFP、CA199阳性率比较,差异无统计学意义(P>0.05);三组CEA、AFP检测阳性率比较,差异无统计学意义(P>0.05),恶性肿瘤组CA199、CA153、CA125分别为(150.89±7.06)、(107.57±4.24)、(446.19±10.07)U/ml,良性肿瘤组分别为(44.31±3.82)、(17.15±1.38)、(52.43±5.65)U/ml,均高于对照组[(12.19±0.93)、(8.02±0.46)、(15.02±2.18)U/ml],差异均有统计学意义(P<0.05)。结论血清肿瘤标志物检测应用于盆腔良恶性妇科肿瘤诊断中,临床价值较高,利于治疗方案的制定。

Objective To investigate the diagnosis and differential significance of serum tumor markers in pelvic benign and malignant gynecological tumors.Methods Fifty patients with pelvic gynecologic tumor in our hospital from July 5 to December 23,2016 were selected as the research object,According to the nature of the tumor was divided into benign and malignant group（25 cases）,and 50 healthy subjects were taken as control group.All patients were given serum tumor markers to detect the detection of positive and biochemical indicators.Results The positive rate of CA153,CA125 of malignant group were 52.00%,92.00%,higher than the benign group （4.00%,60.00%）,the difference was statistically sig- nificant（P〈0.05）,The positive rate of CEA,AFP,CA199 in the two groups had,no significant difference（P〉0.05）;CEA,AFP of the three groups had no statistical significance （P〉0.OS）.In the malignant groups,CA199,CA153,CA125,respectively were[（150.89±7.06）,（107.57±4.24）,（446.19±10.07）U/ml],benign tumor group [（44.31±3.82）,（17.15±l.38）,（52.43±5.65）U/ml], were higher than [12.19±0.93）,（8.02±0.46）,（15.02±2.18）U/ml] of the control group,was statistically significant （P〈0.05）. Conclusion The detection of serum tumor markers in the diagnosis of pelvic benign and malignant gynecological tu- mors has a high clinical value and is favorable to the development of treatment regimens.